Therapeutic and adverse effects of standarddose and low-dose meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients

Journal of Pakistan Association of Dermatologists

Volumn 24, Issue 2, 2014, Pages 115-121

  Shanehsaz, Siavash M ^a   Ishkhanian, Silva ^a  

^a Aleppo University Hospital   (Syrian Arab Republic)

Author keywords

Adverse effects; Cutaneous leishmaniasis; Meglumine antimoniate; Syria

Indexed keywords

MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CARDIOTOXICITY; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DRUG INTOXICATION; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; FEVER; HUMAN; INJECTION SITE INFLAMMATION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NAUSEA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; SKIN LEISHMANIASIS; SWELLING; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; URTICARIA; VOMITING;

EID: 84906093026     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27:305-18.
2. Corrado M. Sul Bottone di Aleppo. Stabilimento Tipografico dei Segretari Comunali, Napoli [in Italian]. 1892.
3. Belazzoug S, Pratlong F, Rioux JA. Un nouveau zymogeme de Leishmania tropica, agent du Bouton d'Alep (Syrie). Arch Inst Pasteur Alger. 1988;56:95-9.
4. Depaquit J, Ferte H, Leger N et al. ITS 2 sequences heterogeneity in Phlebotomus sergenti and Phlebotomus similis (Diptera, Psychodidae): possible consequences in their ability to transmit Leishmania tropica. Int J Parasitol. 2002;32:1123-31.
5. Hepburn NC. Cutaneous leishmaniasis. Clin Exp Dermatol. 2000;25:363-70.
6. Herwalt BL. Leishmaniasis. Lancet 1999;354:1191-9.
7. Voller A, Shaw JJ, Bryant C. The effects of two antimony drugs on the in vitro metabolism of radioactive glucose forms of Leishmania tropica. Ann Trop Med Parasitol. 1963;57:404-8.
8. Berman JD, Waddell D, Hanson BC. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother. 1985;27:916-20.
9. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis. 1980;142:83-6.
10. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials. J Am Acad Dermatol. 2007;57:335.e1-29.
11. Josephson ME, Zimetbaum P. The bradyarrhythmias: disorders of sinus node function and AV conduction disturbances. In: Kasper DL, Braunwald E, Fauci AS et al., editors. Harrison's Principles of Internal Medicine. 16th edn. New York: McGraw Hill; 2005. P. 1333-42.
12. Conizares O, editor. Clinical Tropical Dermatology. Oxford: Blackwell Scientific Publication; 1975. P. 185-204.
13. Marintclle C. The control of leishmaniasis. Bull WHO. 1980:58:807-18.
14. Petersen EA, Neva FA, Barral A et al. Monocyte suppression of antigen specific responses in diffuse cutaneous leishmaniasis patients, Dominican republic. J Immunol. 1984;132:2603-6.
15. World Health Organization: The Leishmaniasis. Report of a WHO expert committee. WHO Technical Report Series 701, 1984.
16. nd edn. New York: McGraw-Hill; 1990. P. 296-307.
17. Berman JD. Human leishmaniasis: Clinical, diagnostic and therapeutic developments in the last 10 years. Clin Infect Dis. 1997;24:684-703.
18. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis, new approaches to disease control. BMJ. 2003;326:377-82.
19. Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191-9.
20. Weigle K, Saravia NG. Natural history, clinical evolution and the host-parasite interaction in new world cutaneous leishmaniasis. Clin Dermatol. 1996;14:433- 50.
21. Oliveira-Neto MP, Schubuch A, Mattos SM et al. A low dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow up studies (up to 10 years). Am J Trop Med Hyg. 1997;57:651-5.
22. Oliveira-Neto MP, Schubach A, Mattos SM et al. Treatment of American cutaneous leishmaniasis: a comparison between low dose (5 mg/kg/d) and high dosage (20 mg/kg/d) antimony regimens. Pathol Biol (Paris). 1997;45:496-9.
23. Chulay J, Auzez E, Kerch D et al. High dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. Trans R Soc Trop Med Hyg. 1981;77:717-21.
24. Harman PRM. Leishmaniasis. In: Rock A, Wilkinson DS, Ebring FJO, editors. Textbook of Dermatology. Oxford: Blackwell Scientific Publications; 1979. P. 901-4.
25. Dostrovsky A, Cohen H. Treatment of late cutaneous leishmaniasis by simultaneous intralesional steroid and intramuscular antimony. Dermatol Internal. 1976;6:172-3.
26. Beheshti M, Ghotbi Sh, Amirizade S. Therapeutic and adverse effects of Glucantime used for treatment of cutaneous leishmaniasis. Shiraz E-Med J. 2007;8:13.